{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:10:52Z","timestamp":1789193452152,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102080649"],"award-info":[{"award-number":["202102080649"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Insulin resistance (IR) plays an important role in the development of non-alcoholic fatty liver disease (NAFLD). IR markers are divided into two types: (1) insulin-based IR marker, homeostatic model assessment of IR (HOMA-IR); and (2) non-insulin-based IR markers, such as triglyceride-glucose (TyG) index, TyG index with body mass index (TyG-BMI), triglyceride\/high-density lipoprotein cholesterol ratio (TG\/HDL-c), and metabolic score for IR (METS-IR). The non-insulin-based IR markers are often associated with lipids. The aim of this study was to analyse the association between IR markers and NAFLD in non-diabetic population. Baseline data of NAFLD and non-NAFLD groups were compared. Logistic regression was used to evaluate the relationship between five IR markers and NAFLD risk. The odds ratios (ORs) and 95% confidence intervals (CIs) of IR markers were calculated. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate the ability of different IR markers to detect NAFLD. Subgroup analyses were performed in obese and non-obese subgroups. This study found a positive correlation between NAFLD risk and elevation in five IR markers (HOMA-IR, TyG, TyG-BMI, TG\/HDL-c, and METS-IR). In non-obese subjects, the AUC of TyG-BMI was larger than that of the other four IR markers to detect NAFLD. The AUC of HOMA-IR was larger than that of the other four IR markers to detect NAFLD in obese subjects. In non-diabetic population, the five IR markers are associated with the risk of NAFLD, including non-obese and obese NAFLD. TyG-BMI and HOMA-IR can be used to detect non-obese and obese NAFLD, respectively, with better detection ability compared with the other IR markers.<\/jats:p>","DOI":"10.1038\/s41598-023-47269-4","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T07:03:04Z","timestamp":1700636584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population"],"prefix":"10.1038","volume":"13","author":[{"given":"Pei","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangsheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"47269_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. The Lancet 397, 2212\u20132224. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3 (2021).","journal-title":"The Lancet"},{"key":"47269_CR2","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology 71, 1851\u20131864. https:\/\/doi.org\/10.1002\/hep.31150 (2020).","journal-title":"Hepatology"},{"key":"47269_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"47269_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li, J. et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 4, 389\u2013398. https:\/\/doi.org\/10.1016\/S2468-1253(19)30039-1 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"47269_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/joim.13069","volume":"228","author":"B Zou","year":"2020","unstructured":"Zou, B. et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999\u20132016. J. Intern. Med. 228, 139\u2013151. https:\/\/doi.org\/10.1111\/joim.13069 (2020).","journal-title":"J. Intern. Med."},{"key":"47269_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep4.1124","volume":"2","author":"H Hagstr\u00f6m","year":"2018","unstructured":"Hagstr\u00f6m, H. et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol. Commun. 2, 48\u201357. https:\/\/doi.org\/10.1002\/hep4.1124 (2018).","journal-title":"Hepatol. Commun."},{"key":"47269_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cgh.2016.08.028","volume":"15","author":"D Kim","year":"2017","unstructured":"Kim, D. & Kim, W. R. Nonobese fatty liver disease. Clin. Gastroenterol. Hepatol. 15, 474\u2013485. https:\/\/doi.org\/10.1016\/j.cgh.2016.08.028 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"47269_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/biomedicines10010015","volume":"10","author":"V Dorairaj","year":"2022","unstructured":"Dorairaj, V., Sulaiman, S.A., Abu, N. & Abdul Murad, N.A. Nonalcoholic fatty liver disease (NAFLD): Pathogenesis and noninvasive diagnosis. Biomedicines 10, 15.\u00a0https:\/\/doi.org\/10.3390\/biomedicines10010015 (2022).","journal-title":"Biomedicines"},{"key":"47269_CR9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt, M. J., Miotto, P. M., Nardo, W. D. & Montgomery, M. K. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr. Rev. 40, 1367\u20131393. https:\/\/doi.org\/10.1210\/er.2019-00034 (2019).","journal-title":"Endocr. Rev."},{"key":"47269_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hep.30429","volume":"70","author":"RS Khan","year":"2019","unstructured":"Khan, R. S., Bril, F., Cusi, K. & Newsome, P. N. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology 70, 711\u2013724. https:\/\/doi.org\/10.1002\/hep.30429 (2019).","journal-title":"Hepatology"},{"key":"47269_CR11","doi-asserted-by":"publisher","first-page":"e0255535","DOI":"10.1371\/journal.pone.0255535","volume":"16","author":"DJ Koo","year":"2021","unstructured":"Koo, D. J. et al. Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. PLoS ONE 16, e0255535. https:\/\/doi.org\/10.1371\/journal.pone.0255535 (2021).","journal-title":"PLoS ONE"},{"key":"47269_CR12","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.1152\/ajpendo.1979.237.3.E214","volume":"237","author":"RA DeFronzo","year":"1979","unstructured":"DeFronzo, R. A., Tobin, J. D. & Andres, R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214\u2013E223. https:\/\/doi.org\/10.1152\/ajpendo.1979.237.3.E214 (1979).","journal-title":"Am. J. Physiol."},{"key":"47269_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/bf00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: Insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419. https:\/\/doi.org\/10.1007\/bf00280883 (1985).","journal-title":"Diabetologia"},{"key":"47269_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.20945\/2359-3997000000533","volume":"67","author":"CC Silva","year":"2023","unstructured":"Silva, C. C. et al. The threshold value for identifying insulin resistance (HOMA-IR) in an admixed adolescent population: A hyperglycemic clamp validated study. Arch. Endocrinol. Metab. 67, 119\u2013125. https:\/\/doi.org\/10.20945\/2359-3997000000533 (2023).","journal-title":"Arch. Endocrinol. Metab."},{"key":"47269_CR15","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.2147\/DMSO.S409983","volume":"16","author":"H Li","year":"2023","unstructured":"Li, H. et al. Relationship between six insulin resistance surrogates and nonalcoholic fatty liver disease among older adults: A cross-sectional study. Diabetes Metab. Syndr. Obes. 16, 1685\u20131696. https:\/\/doi.org\/10.2147\/DMSO.S409983 (2023).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"47269_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.21037\/hbsn-20-263","volume":"10","author":"PF Hu","year":"2021","unstructured":"Hu, P. F. et al. The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: A population-based cross-sectional study. Hepatobiliary Surg. Nutr. 10, 811\u2013824. https:\/\/doi.org\/10.21037\/hbsn-20-263 (2021).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"47269_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12933-022-01648-9","volume":"21","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z., Zhang, L., Jiang, W., Du, T. & Yuan, G. Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients. Cardiovasc. Diabetol. 21, 210. https:\/\/doi.org\/10.1186\/s12933-022-01648-9 (2022).","journal-title":"Cardiovasc. Diabetol."},{"key":"47269_CR18","doi-asserted-by":"publisher","first-page":"1224967","DOI":"10.3389\/fendo.2023.1224967","volume":"14","author":"T Qian","year":"2023","unstructured":"Qian, T. et al. Mets-IR as a predictor of cardiovascular events in the middle-aged and elderly population and mediator role of blood lipids. Front. Endocrinol. 14, 1224967. https:\/\/doi.org\/10.3389\/fendo.2023.1224967 (2023).","journal-title":"Front. Endocrinol."},{"key":"47269_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12902-022-00993-w","volume":"22","author":"N Li","year":"2022","unstructured":"Li, N. et al. Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes. BMC Endocr. Disord. 22, 101. https:\/\/doi.org\/10.1186\/s12902-022-00993-w (2022).","journal-title":"BMC Endocr. Disord."},{"key":"47269_CR20","doi-asserted-by":"publisher","first-page":"1083032","DOI":"10.3389\/fendo.2023.1083032","volume":"14","author":"H Peng","year":"2023","unstructured":"Peng, H. et al. Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in US adults. Front. Endocrinol. 14, 1083032. https:\/\/doi.org\/10.3389\/fendo.2023.1083032 (2023).","journal-title":"Front. Endocrinol."},{"key":"47269_CR21","doi-asserted-by":"publisher","first-page":"4930355","DOI":"10.1155\/2022\/4930355","volume":"2022","author":"X Cai","year":"2022","unstructured":"Cai, X. et al. Dose-response associations of metabolic score for insulin resistance index with nonalcoholic fatty liver disease among a nonobese Chinese population: Retrospective evidence from a population-based cohort study. Dis. Mark. 2022, 4930355. https:\/\/doi.org\/10.1155\/2022\/4930355 (2022).","journal-title":"Dis. Mark."},{"key":"47269_CR22","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/apt.12963","volume":"40","author":"L Fedchuk","year":"2014","unstructured":"Fedchuk, L. et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol. Ther. 40, 1209\u20131222. https:\/\/doi.org\/10.1111\/apt.12963 (2014).","journal-title":"Aliment Pharmacol. Ther."},{"key":"47269_CR23","doi-asserted-by":"publisher","first-page":"e7041","DOI":"10.1097\/MD.0000000000007041","volume":"96","author":"S Zhang","year":"2017","unstructured":"Zhang, S. et al. Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects. Medicine 96, e7041. https:\/\/doi.org\/10.1097\/MD.0000000000007041 (2017).","journal-title":"Medicine"},{"key":"47269_CR24","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1861-23","author":"Y Ito","year":"2023","unstructured":"Ito, Y. et al. Prevalence of non-alcoholic fatty liver disease detected by computed tomography in the general population compared with ultrasonography. Intern. Med. https:\/\/doi.org\/10.2169\/internalmedicine.1861-23 (2023).","journal-title":"Intern. Med."},{"key":"47269_CR25","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/hep.23567","volume":"51","author":"K Das","year":"2010","unstructured":"Das, K. et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51, 1593\u20131602. https:\/\/doi.org\/10.1002\/hep.23567 (2010).","journal-title":"Hepatology"},{"key":"47269_CR26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. The Asian Pacific Association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. 14, 889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2 (2020).","journal-title":"Hepatol. Int."},{"key":"47269_CR27","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3350\/cmh.2022.0070","volume":"28","author":"CH Ng","year":"2022","unstructured":"Ng, C. H., Huang, D. Q. & Nguyen, M. H. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. Clin. Mol. Hepatol. 28, 790\u2013801. https:\/\/doi.org\/10.3350\/cmh.2022.0070 (2022).","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47269-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47269-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47269-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T07:10:11Z","timestamp":1700637011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47269-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47269"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47269-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"1 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20470"}}